alimera
sciences
signs
distribution
agreement
medis
pharmaceutical
commercialize
austria
czech
republic
nasdaq
alim
atlanta
globe
newswire
alimera
sciences
nasdaq
alim
alimera
pharmaceutical
company
specializes
development
commercialization
prescription
ophthalmic
pharmaceuticals
announces
alimera
sciences
europe
limited
european
subsidiary
signed
distribution
agreement
medis
pharmaceutical
company
medis
exclusive
sales
distribution
czech
republic
austria
iluvien
alimera
sustained
release
intravitreal
injection
approved
countries
treatment
vision
impairment
associated
chronic
diabetic
macular
edema
dme
considered
insufficiently
responsive
available
therapies
prevention
relapse
recurrent
uveitis
affecting
posterior
segment
nipu
medis
immediately
assume
responsibility
promotion
marketing
commercial
activities
austria
iluvien
currently
reimbursed
additionally
medis
commence
negotiations
czech
republic
state
institute
drug
control
regarding
appropriate
public
price
confidential
net
price
reimbursement
iluvien
advance
initiation
promotion
marketing
commercial
activities
agreement
furthers
alimera
strategic
objective
continue
increasing
availability
iluvien
additional
european
countries
treat
patients
suffering
dme
nipu
said
rick
eiswirth
president
chief
executive
officer
alimera
medis
strong
growth
commitment
markets
makes
partner
choice
pleased
working
expand
iluvien
franchise
extremely
pleased
partner
alimera
offer
iluvien
customers
austria
czech
republic
added
martina
perharic
medis
chief
executive
officer
iluvien
continuous
microdosingtm
technology
enables
consistent
treatment
every
day
three
years
reduce
recurrence
disease
believe
highly
important
physicians
patients
iluvien
alimera
primary
product
iluvien
fluocinolone
acetonide
intravitreal
implant
mg
sustained
release
intravitreal
implant
injected
back
eye
continuous
technology
iluvien
designed
release
levels
fluocinolone
acetonide
corticosteroid
months
reduce
recurrence
disease
enabling
patients
maintain
vision
longer
fewer
injections
iluvien
approved
canada
kuwait
lebanon
treat
diabetic
macular
edema
dme
patients
previously
treated
course
corticosteroids
clinically
significant
rise
intraocular
pressure
european
countries
iluvien
indicated
treatment
vision
impairment
associated
chronic
dme
considered
insufficiently
responsive
available
therapies
march
iluvien
received
approval
countries
mutual
recognition
procedure
prevention
relapse
recurrent
uveitis
affecting
posterior
segment
eye
european
countries
include
germany
france
italy
spain
portugal
ireland
austria
belgium
denmark
norway
finland
sweden
poland
czech
republic
netherlands
luxembourg
posterior
uveitis
indication
iluvien
launched
germany
iluvien
approved
treatment
uveitis
united
states
diabetic
macular
edema
dme
dme
primary
cause
vision
loss
associated
diabetic
retinopathy
disease
affecting
macula
part
retina
responsible
central
vision
blood
vessel
leakage
associated
diabetic
retinopathy
results
swelling
macula
condition
called
dme
onset
dme
painless
may
go
unreported
patient
manifests
blurring
central
vision
acute
vision
loss
severity
blurring
may
range
mild
profound
loss
vision
wisconsin
epidemiologic
study
diabetic
retinopathy
found
period
approximately
people
diabetes
included
study
diagnosed
dme
people
type
type
diabetes
risk
developing
dme
posterior
uveitis
nipu
posterior
segment
uveitis
chronic
inflammatory
disease
affecting
posterior
segment
eye
often
involving
retina
leading
cause
blindness
developed
developing
countries
affects
people
ages
producing
swelling
destroying
eye
tissues
lead
severe
vision
loss
blindness
patients
nipu
typically
treated
systemic
steroids
effective
time
frequently
lead
serious
side
effects
ranging
acne
weight
gain
sleep
mood
disorders
hypertension
osteoporosis
limit
effective
dosing
patients
often
progress
therapy
systemic
immune
suppressants
biologics
also
severe
side
effects
including
increased
risk
cancer
infection
result
remains
significant
need
new
therapies
improved
efficacy
tolerability
safety
profiles
manage
disease
alimera
sciences
alimera
sciences
pharmaceutical
company
specializes
commercialization
development
prescription
ophthalmic
pharmaceuticals
alimera
presently
focused
diseases
affecting
back
eye
retina
diseases
well
treated
current
therapies
affect
millions
people
aging
populations
information
please
visit
medis
medis
pharmaceutical
company
leading
independent
medical
marketing
company
focused
commercialization
innovative
pharmaceutical
products
emphasis
specialty
drugs
medical
equipment
brands
medis
aims
making
advanced
effective
medical
treatments
accessible
every
patient
central
eastern
europe
cee
region
represent
million
potential
customers
fully
owned
subsidiaries
across
cee
region
leveraging
marketing
scientific
expertise
product
knowledge
headquartered
ljubljana
slovenia
founded
employs
learn
medis
en
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
regarding
among
things
alimera
expectations
respect
medis
success
managing
negotiations
funding
czech
republic
promoting
iluvien
austria
czech
republic
statements
based
current
expectations
involve
inherent
risks
uncertainties
including
factors
could
delay
divert
change
company
expectations
could
cause
actual
results
differ
materially
projected
statements
meaningful
factors
could
cause
actual
results
differ
include
limited
acceptance
iluvien
payers
czech
republic
medis
ability
launch
iluvien
austria
czech
republic
medis
ability
provide
adequate
promotion
marketing
commercial
support
iluvien
acceptance
physicians
austria
czech
republic
iluvien
use
dme
nipu
patients
well
factors
discussed
risk
factors
management
discussion
analysis
financial
condition
results
operations
sections
alimera
annual
report
form
year
ended
december
quarterly
reports
form
quarters
ended
march
june
file
securities
exchange
commission
sec
available
sec
website
statements
contained
press
release
expressly
qualified
cautionary
statements
contained
referred
herein
alimera
cautions
investors
rely
heavily
statements
alimera
makes
made
behalf
statements
speak
date
press
release
unless
another
date
indicated
alimera
undertakes
obligation
specifically
declines
obligation
publicly
update
revise
statements
whether
result
new
information
future
events
otherwise
press
inquiries
jules
abraham
alimera
sciences
julesa
investor
inquiries
scott
gordon
alimera
sciences
scottg
